

VERTEX PHARMACEUTICALS INC.

ISIN: US92532F1003 WKN: 92532F100 Asset Class: **Stock**

Company



2023/06/02 22:00:00

Price
333.78
USD

Difference ▲ 3.14%(10.16)



Contact Details

VERTEX PHARMACEUTICALS
INC.

--

50 Northern Avenue

02210 Boston

Tel: +1-617-341-6100

Fax: +

Web: <http://www.vrtx.com>

E-mail:
mediainfo@vrtx.com

Company Profile

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2022		2021		2020	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	13,234,800,000		9,560,600,000		8,133,379,000	
Common stock capital		2,600,000		2,500,000		2,599,000
Fixed assets	4,916,100,000		3,871,900,000		3,618,429,000	
Equity capital of a company		13,912,700,000		10,100,000,000		8,686,815,000
Cash and cash equivalents	10,512,000,000		6,800,100,000		5,988,845,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		2,742,100,000		2,142,000,000		1,877,533,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		1,496,100,000		1,190,500,000		1,187,460,000
Different income		-		-		-
Other liabilities		685,800,000		303,300,000		297,955,000
Total assets	18,150,900,000	18,150,900,000	13,432,500,000	13,432,500,000	11,751,808,000	11,751,808,000

Balance notes

	2022	2021	2020
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	4,800	3,900	3,400
Equity ratio	76.65%	75.19%	73.92%
Debt-equity ratio	30.46%	33.00%	35.28%

Others

	2022	2021	2020
Tax Expense Rate	21.51%	14.22%	13.00%

VERTEX PHARMACEUTICALS INC.

ISIN: US92532F1003 WKN: 92532F100 Asset Class: Stock

Income statement

	2022	2021	2020
Turnover	8,748,200,000	7,604,400,000	6,209,397,000
Net income	3,322,000,000	2,342,100,000	2,711,647,000
EBIT	3,874,159,520	2,606,402,400	2,948,414,392
Operating income before taxes	4,232,400,000	2,730,400,000	3,116,798,000
Cash Flow	4,129,900,000	2,643,500,000	3,253,505,000
Net interest income	89,800,000	-56,600,000	-35,912,000
Research and development expenses	2,642,800,000	3,051,100,000	1,829,537,000
Income taxes	910,400,000	388,300,000	405,151,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	1,704,441	1,823,496	1,707,949

Board of Directors

Members of Management Board

Jeffrey Leiden	Chairman of Board of Directors
Alan Garber	Member of Board of Directors
Sangeeta Bhatia	Member of Board of Directors
Bruce Sachs	Member of Board of Directors
Diana McKenzie	Member of Board of Directors
Lloyd Carney	Member of Board of Directors
Suketu Upadhyay	Member of Board of Directors
Terrence Kearney	Member of Board of Directors
Reshma Kewalramani, M.D.	Chairman of Managing Board
David Altshuler	Member of Executive Committee
Jeffrey Leiden	Member of Executive Committee
Amit K. Sachdev	Member of Executive Committee
Bastiano Sanna, Ph.D.	Member of Executive Committee
Carmen Bozic, M.D.	Member of Executive Committee
Charles F. Wagner, Jr.	Member of Executive Committee
Damian Wirmot	Member of Executive Committee
Joy Liu	Member of Executive Committee
Ludovic Fenaux	Member of Executive Committee
Mark Bunnage	Member of Executive Committee
Michael Partridge	Member of Executive Committee
Mike Tirozzi	Member of Executive Committee
Nia Tatsis, Ph.D.	Member of Executive Committee
Nina Devlin	Member of Executive Committee
Paul Negulescu	Member of Executive Committee
Stephanie Franklin	Member of Executive Committee